Sichenzia Ross Friedman Ference LLP Represents Citius Pharmaceuticals Inc. in connection with its acquisition of LM Biosciences, Inc.
Press Release – New York, NY – March 8, 2016 – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that it has represented Citius in its acquisition of LM Biosciences, Inc. (“LMB”). LMB is a late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration of anti-infective drugs.
The acquisition was an all stock transaction and included a $3 million investment by Citius’ Chairman of the Board. The Sichenzia Ross Friedman Ference LLP was led by Partners Arthur Marcus, Gregory Sichenzia and associate Nazia Khan.
.jpg)
Sichenzia Ross Ference LLP
Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.
Visit SRF's LinkedIn page
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference Closes $180 Million Real Estate Portfolio Acquisition on Behalf of Client - April 20, 2019
- Partner Mendy Piekarski Achieves Complete Dismissal for SRF Client - April 19, 2019
- Sichenzia Ross Ference LLP Represents Quest Solutions, Inc. in $5 Million Private Placement - April 10, 2019
